杨鹏，教授、博士生导师、原创药物技术创新研究院副院长、药物化学系主任，入选国家高层次青年人才（2018年）、江苏省“双创人才”（2019年）和“双创团队领军人才”（2020年）、江苏省百篇优秀博士学位论文指导教师（2022年）、中国药科大学“兴药领军学者”（2022年）。

  致力于癌症、代谢性疾病相关的靶标发现与小分子药物研究，发表学术论文60余篇，其中以通讯或第一作者在Nat. Commun. （3篇）、Leukemia、Acta Pharm Sin B（5篇）、J. Med. Chem.（10篇，含2篇封面）、Eur. J. Med. Chem. （4篇）等发表论文36篇；主持国家重点研发计划课题、国自然面上、省双创团队等纵向科研项目19项；申请专利32项（国际9项），16项已获得授权；主持或参与完成多项新药研究，五个候选药物成功转让给医药企业（总额1.76亿），一个已完成II期临床研究。

  目前，担任《中国药物评价》编委、《中国药科大学学报》编委、《药学进展》青年编委、《药学学报》和Acta Pharm Sin B青年编委，中国药学会老年药学专业委员会委员、中国生物医药产业链创新与转化联盟药物研发专业委员会副主委。

1.         Dong H.#, Ye X.#, Zhu Y.#, Shen H., Shen H., Chen W., Ji M., Zheng M., Wang K., Cai Z., Sun H.*, Xiao Y.*, Yang P.*. Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC. J. Med. Chem. 2023, 66, 6849-6868.

2.         Yuan K.#, Shen H.#, Zheng M.#, Xia F.#, Li Q., Chen W., Ji M., Yang H., Zhuang X., Cai Z., Min W., Wang X.*, Xiao Y.*, Yang P.*. Discovery of potent DYRK2 inhibitors with high selectivity, great solubility, and excellent safety properties for the treatment of prostate cancer. J. Med. Chem. 2023, 66, 4215-4230 (封面文章).

3.         Sun C.#, Yin M.#, Cheng Y.#, Kuang Z., Liu X., Wang G., Wang X., Yuan K., Min W., Dong J., Hou Y., Hu L., Zhang G., Pei W., Wang L., Sun Y., Yu X., Xiao Y.*, Deng H.*, Yang P.*. Novel small-molecule PD-L1 inhibitor induces PD-L1 internalization and optimizes the immune microenvironment. J. Med. Chem. 2023, 66, 2064-2083 (封面文章).

4.         Ding J.#, Shen H.#, Wang D.#, Kuang W., Wang L., Wang X.*, Yang P.*. Pan-cancer analysis of DNA methyltransferase family with potential implications in prognosis and immunology in human cancer. Genes & Diseases, 2022, https://doi.org/10.1016/j.gendis.2022.07.016.

5.         Sun C.#, Cheng Y.#, Liu X.#, Wang G., Min W., Wang X., Yuan K., Hou Y., Li J., Zhang H., Dong H., Wang L., Lou C., Sun Y., Yu X., Deng H.*, Xiao Y.*, Yang P.*. Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents. Acta Pharm. Sin. B 2022, 12(12): 4446-4457.

6.         Chen W.#, Ji M.#, Cheng H.#, Zheng M., Xia F., Min W., Yang H., Wang X., Wang L., Cao L.*, Yuan K.*, Yang P.*. Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer. J. Med. Chem. 2022, 65, 22, 15102-15122.

7.         Kuang W. #, Zhang H.#, Wang X., Yang P.*. Overcoming Mycobacterium tuberculosis through small molecule inhibitors to break down cell wall synthesis. Acta Pharm. Sin. B 2022, 12(8):3201-3214.

8.         Hou Y.#, Zhang F.#, Min W.#, Yuan K., Kuang W., Wang X., Zhu Y., Sun C., Xia F., Wang Y., Zhang H., Wang L., Yang P.*. Discovery of Novel Phosphoinositide-3-Kinase α Inhibitors with High Selectivity, Excellent Bioavailability, and Long-Acting Efficacy for Gastric Cancer. J. Med. Chem. 2022, 65, 9873-9892.

9.         Wang X.#*, Kuang W.#, Ding J.#, Li J., Ji M., Chen W., Shen H., Shi Z., Wang D., Wang L., Yang P.*. Systematic identification of the RNA-binding protein STAU2 as a key regulator of pancreatic adenocarcinoma, Cancers 2022, 14(15), 3629.

10.     Li J.#, Wang X.#, Ding J., Zhu Y., Min W., Kuang W., Yuan K., Sun C., Yang P.*, Development and clinical advancement of small molecules for ex vivo expansion of hematopoietic stem cell. Acta Pharm. Sin. B 2022, 12(6): 2808-2831.

11.     Yuan K.#, Li Z.#, Kuang W.#, Wang X.#, Ji M., Chen W., Li J., Min W., Sun C., Ye X., Lu M., Wang L., Ge H., Jiang Y.*, Hao H.*, Xiao Y.*, Yang P.*. Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) with a highly selective inhibitor for the treatment of prostate cancer, Nat. Commun. 2022, 13:2903.

12.     Kuang W.#, Wang X.#, Ding J.#, Li J., Ji M., Chen W., Wang L., Yang P.*, PTPN2, a key predictor of prognosis for pancreatic adenocarcinoma, significantly regulates cell cycles, apoptosis, and metastasis. Front. Immunol. 2022, 13:805311.

13.     Yuan K.#, Ji M.#, Xie S.#, Qiu Z., Chen W., Min W., Xia F., Zheng M., Wang X., Li J., Hou Y., Kuang W., Wang L., Gu W.*, Li Z.*, Yang P.*, Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia. J. Med. Chem. 2022, 65(1), 857-875.

14.     Hou Y., Kuang W., Min W., Liu Z., Zhang F., Yuan K., Wang X., Sun C., Cheng H., Wang L., Xiao Y., Pu S.*, Xin G.*, Yang P.*, Design, Synthesis, and Biological Evaluation of Icaritin Derivatives as Novel Putative DEPTOR Inhibitors for Multiple Myeloma Treatment, J. Med. Chem. 2021, 64, 14942-14954.

15.     Yuan K., Wang X., Dong H., Min W., Hao H.*, Yang P.*, Selective inhibition of CDK4/6: a safe and effective strategy for developing anticancer drugs. Acta Pharm. Sin. B 2021;11(1):30-54.